Trial reportAnnals of clinical and translational neurology2025
Durability of Response to B-Cell Maturation Antigen-Directed mRNA Cell Therapy in Myasthenia Gravis.
Trial report in Annals of clinical and translational neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04146051 (Autologous T-Cells Expressing A Chimeric Antigen Receptor Directed To B-Cell Maturation Antigen), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Autologous T-Cells Expressing A Chimeric Antigen Receptor Directed To B-Cell Maturation Antigen (BCMA) In Patients With Generalized Myasthenia Gravis (MG)
Who cites it
13 citing papers in PubMed.
- BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.Nature medicine · 2026Trial
- BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial.Nature medicine · 2026Trial
- Long-term outcomes of anti-CD19 CAR T cell therapy in refractory myasthenia gravis: A case series.Cell reports. Medicine · 2026Article
- Resetting autoimmune disease with CAR cell therapies.Nature medicine · 2026Review
- Chimeric Antigen Receptor T-Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions.Muscle & nerve · 2026Review
- The in vivo revolution in CAR-T therapy medicinal products: challenges and regulatory prospects.Signal transduction and targeted therapy · 2026Review
- Burden of Disease in Myasthenia Gravis: A Targeted Literature Review.Journal of neurology · 2026Review
- Clinical progress of engineered cellular immunotherapies for autoimmunity.Nature biotechnology · 2026Review
- Neurological implications of chimeric antigen receptor-T cell therapy.BMJ neurology open · 2026Review
- The prospects of CAR T-cell therapies in changing the therapeutic algorithm of neurologic autoimmunities.Therapeutic advances in neurological disorders · 2026Review
- Chimeric antigen receptor T-cell therapy in neuroimmune diseases: mechanistic rationale, clinical experience, and translational challenges.Frontiers in immunology · 2026Review
- Chimeric antigen receptor T cell therapy in autoimmune neurological disease: current status of efficacy and safety.BMJ neurology open · 2026Review
- CAR T Cell Therapy for Rheumatoid Arthritis.Clinical reviews in allergy & immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveWe report the 12-month follow-up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes-08, a BCMA-directed RNA chimeric antigen receptor T-cell (rCAR-T) therapy for refractory generalized myasthenia gravis (MG). These findings provide insight into the potential applicability of BCMA-targeted rCAR-T therapy for antibody-mediated autoimmune diseases.
methodsIn the Phase 2a part of the study, Descartes-08 was administered at 52.5 × 10
resultsAll seven participants who received six weekly infusions of Descartes-08 exhibited clinically meaningful improvement in common MG severity scales (MG Composite, MG Activities of Daily Living, Quantitative MG scores, and Quality of Life 15-revised) at Month 3 without significant toxicity. At Month 9 follow-up, all participants continued to experience marked clinically meaningful improvements. Five out of seven participants maintained the response at Month 12. A third participant experienced a relapse approximately 6 months after completing on-study follow-up. All three participants who experienced loss of clinical effects were retreated. Two had rapid improvement in clinical scores with minimal symptom expression at Week 8, which was maintained through 12 months of retreatment follow-up. The third participant experienced similar improvement in MG severity scores to their initial treatment.
interpretationThese data support continued development of Descartes-08 in myasthenia gravis and other autoantibody-associated autoimmune disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.